Advancing therapy for hypercholesterolemia (Q37761373)

22 August 2017

1 reference

title

Advancing therapy for hypercholesterolemia (English)

1 reference

Christodoulos I. Stefanadis

22 August 2017

0 references

series ordinal

4

object named as

Christodoulos Stefanadis

1 reference

22 August 2017

3

Ioannis Skoumas

1 reference

PubMed ID

20509773

22 August 2017

Konstantinos Toutouzas

series ordinal

1

object named as

Konstantinos Toutouzas

1 reference

22 August 2017

Maria Drakopoulou

2

1 reference

PubMed ID

20509773

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

10

1 reference

22 August 2017

1659-1672

1 reference

The statins in preventive cardiology.

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Evidence mandating earlier and more aggressive treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Intestinal cholesterol transport proteins: an update and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Intracellular assembly of VLDL: two major steps in separate cell compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Regulation of intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

The differential hepatic uptake of chylomicron remnants of different fatty acid composition is not mediated by hepatic lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

NPC1L1: evolution from pharmacological target to physiological sterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

High-density lipoprotein cholesterol and the role of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Pleiotropic effects and cholesterol-lowering therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Mechanisms of plaque stabilization with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Safety considerations with gastrointestinally active lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Rediscovering bile acid sequestrants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Bile acid sequestrants as a therapeutic option for glucose lowering in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Lipid-lowering drugs acting at the level of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Statin therapy with ezetimibe or niacin in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regressio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Combination statin-fibrate therapy: safety aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Myopathy with statin-fibrate combination therapy: clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Fish and omega-3 fatty acid intake and risk of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Niacin therapy in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Apolipoprotein A-I(Milano): current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003774080

10.1517/14656561003774080

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20509773